French agency seeks standard use of special healthcare products:
This article was originally published in Clinica
Executive Summary
The French healthcare products safety agency, AFSSAPS, issued an update on September 8 concerning the use in French hospitals of products that are reimbursed separately from the diagnosis-related group scheme (where most health procedures are paid for as standard stay groups - GHSs). The agency is seeking to ensure that all hospitals that use these products conform to the same criteria. To this aim, it is in the process - working along with the Supreme Health Authority (HAS) and the National Cancer Institute (INCa) - of drawing up reference standards that are to be posted on the websites of the three organisations. The update is on the availability of information on pharmaceuticals, but is also a reminder that more uniform criteria are soon to be applied.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.